This study will compare four different semaglutide versions and different injection tools. The study aims to show similar levels of semaglutide in the blood using different versions of semaglutide. The researchers also want to look at how well the injection tools work. Participants will get two versions of semaglutide at two separate dosing visits. One of them is a version that doctors already can prescribe and the other will be one of the new versions. Which version participants get first is decided by chance. Participants will get semaglutide as an injection under the skin. The time between injections is 7 to 8 weeks. The study will last for about 16 weeks. Participants will have 27 study visits with the study doctor. For two of the visits, participants will stay at the clinic for 4 days and 3 nights.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
68
A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
Novo Nordisk Investigational Site
Mainz, Germany
Novo Nordisk Investigational Site
Neuss, Germany
AUC0-last,sema,SD, the area under the plasma semaglutide concentration curve from time 0 until last quantifiable measurement after a single dose subcutaneous semaglutide administration
Measured in nmol·h/L.
Time frame: 0-840 hours (5 weeks)
Cmax,sema,SD, the maximum plasma semaglutide concentration after a single dose subcutaneous semaglutide administration
Measured in nmol/L.
Time frame: 0-840 hours (5 weeks)
AUC0-∞,sema,SD, the area under the plasma semaglutide concentration curve from time 0 until infinity after a single dose subcutaneous semaglutide administration
Measured in nmol·h/L.
Time frame: 0-840 hours (5 weeks)
tmax,sema,SD, time to Cmax,sema,SD of semaglutide
Measured in hours.
Time frame: 0-840 hours (5 weeks)
t½,sema,SD, terminal elimination half-life of semaglutide
Measured in hours.
Time frame: 0-840 hours (5 weeks)
Cl/F,sema,SD, total apparent clearance of semaglutide
Measured in L/h.
Time frame: 0-840 hours (5 weeks)
Vz/F,sema,SD, apparent volume of distribution of semaglutide
Measured in L.
Time frame: 0-840 hours (5 weeks)
Number of site-initiated technical complaints with or without co-reported adverse events: DV3372 device, 0.5 mg/mL versus PDS290 semaglutide pen-injector, 1.34 mg/mL
Count of technical complaints.
Time frame: Week 0-5 in both treatment period 1 and 2
Number of site-initiated technical complaints with or without co-reported adverse events: DV3372 device, 1.0 mg/mL versus PDS290 semaglutide pen-injector, 1.34 mg/mL
Count of technical complaints.
Time frame: Week 0-5 in both treatment period 1 and 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.